Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 10:30 a.m. ET.
A live webcast will be available in the Investors section of the Maze Therapeutics website and will be archived for 60 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – MAZE
On the day this news was published, MAZE gained 4.26%, reflecting a moderate positive market reaction. This price movement added approximately $88M to the company's valuation, bringing the market cap to $2.16B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer performance is mixed: ORIC +11.09%, ELVN +2.31%, WVE +3.93%, SION +0.89%, and RAPP -3.97%, suggesting stock-specific rather than broad sector-driven trading for MAZE around this conference update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Investor conference | Neutral | +0.3% | Announcement of CEO presentation at Guggenheim biotech summit with webcast access. |
| Jan 05 | Investor conference | Neutral | -2.9% | CEO presentation scheduled for the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 06 | Earnings & pipeline | Neutral | -3.5% | Q3 2025 financials plus positive Phase 1 data and Phase 2 plans for key programs. |
| Nov 06 | Scientific conference | Positive | -2.1% | Seven ASN Kidney Week abstracts highlighting MZE829 and MZE782 mechanistic and translational data. |
| Nov 04 | Multiple conferences | Neutral | -2.5% | Participation in four investor conferences with webcast availability across Nov–Dec 2025. |
Recent conference participation headlines (e.g., Feb 4 and Jan 5) have led to modest single-day moves between about -2.9% and +0.35%, while positive scientific/clinical news like ASN Kidney Week on Nov 6, 2025 saw a negative reaction of -2.11%.
Over the last few months, Maze has frequently highlighted investor and scientific visibility events, including Guggenheim (Feb 11, 2026), J.P. Morgan (Jan 12, 2026), and multiple investor conferences in Nov–Dec 2025. A major update on Nov 6, 2025 combined Q3 2025 financials with positive Phase 1 data for MZE782 and progress for MZE829. Additional kidney program data at ASN Kidney Week followed the same day. Today’s TD Cowen participation continues this pattern of active conference engagement.
Regulatory & Risk Context
An effective S-3ASR automatic shelf filed on Feb 4, 2026 supports an at-the-market program to sell up to $200,000,000 of common stock through Jefferies LLC, with up to 3% commissions. As of the latest context, usage_count is 0, indicating no ATM takedowns have been reported from this shelf.
Market Pulse Summary
This announcement adds another investor touchpoint as Maze’s CEO presents at TD Cowen on March 4, 2026, with a webcast archived for 60 days. It follows a series of conferences and detailed Q3 2025 updates on cash, pipeline progress for MZE782 and MZE829, and an effective $200,000,000 ATM shelf. Investors tracking the story may focus on future clinical readouts, funding usage under the shelf, and any shifts in conference messaging versus prior events.
Key Terms
small molecule medical
precision medicines medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET.
A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentation.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com
FAQ
When will Maze Therapeutics (MAZE) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch the MAZE presentation at the TD Cowen conference on March 4, 2026?
Will the Maze Therapeutics (MAZE) webcast be available after the live TD Cowen presentation?
Who from Maze Therapeutics will present at the March 4, 2026 TD Cowen conference?
What topics will Maze Therapeutics (MAZE) likely cover in the TD Cowen March 4, 2026 presentation?
Where on the Maze Therapeutics website can I find the TD Cowen conference webcast for MAZE?
